Compare TBPH & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | TALK |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | 598 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 872.7M |
| IPO Year | 2013 | N/A |
| Metric | TBPH | TALK |
|---|---|---|
| Price | $16.91 | $5.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $18.40 | $6.42 |
| AVG Volume (30 Days) | 905.3K | ★ 2.7M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | $26.02 |
| Revenue Next Year | N/A | $21.24 |
| P/E Ratio | ★ N/A | $155.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.82 | $2.22 |
| 52 Week High | $21.03 | $5.25 |
| Indicator | TBPH | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 59.24 |
| Support Level | $16.12 | $5.19 |
| Resistance Level | $17.21 | N/A |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 1.75 | 76.92 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Talkspace Inc is a virtual behavioral healthcare company offering its members convenient and affordable access to a fully-credentialed network of qualified providers across a wide and growing spectrum of care through virtual psychotherapy and psychiatry. It is a single destination for comprehensive mental health care, including therapy for individuals, couples, and teens, as well as psychiatric treatment and medication management (18+), and self-guided tools and resources. The company's customers include Health insurance plans from commercial and government institutions, and employee assistance programs, Direct-to-Enterprise, and Individual subscribers. The company operates as a single segment.